Compare Neurocrine Biosciences Inc (NBIX) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs United States Oil ETF — how do they compare? Neurocrine Biosciences Inc trades at $143.3 (market cap $14.36B), while United States Oil ETF trades at $147.84 (market cap $1.90B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.6× United States Oil ETF's market cap, and United States Oil ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and United States Oil ETF for 21 Days on average.
| NBIX | USO | |
|---|---|---|
Market Cap | $14.36B | $1.90B |
Volume | 1,237,180 | 5,932,922 |
Sector | Health | — |
52-Week High | $185.50 | $161.86 |
52-Week Low | $123.10 | $66.17 |
Typical Hold Time | 23 Days | 21 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
USO is trading at $147.835, up 2.73% with a bullish technical signal from moving averages. The stock shows neutral oscillators but faces mixed oil market conditions with Middle East tensions and G-7 reserve releases creating volatility. Recent news highlights supply disruptions and geopolitical risks affecting crude prices.
The outlook remains cautious with geopolitical risks and supply uncertainties balancing against potential price support from production constraints. Investment opportunities exist if supply disruptions persist, but risks include regulatory pressures and volatile oil markets that could impact shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
